Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from iex and EODHD
Download Data

Monte Rosa Therapeutics Inc Income Statement 2020 - 2024

This table shows the Income Statement for Monte Rosa Therapeutics Inc going from 2020 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31
Revenue
M 1 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue
M 2 2 2 1 1 3 - - - - - - - - - - -
Gross Profit
M -1 7 -2 -1 -1 -3 - - - - - - - - - - -
Operating Expenses
M 34 42 35 36 33 30 - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 9 8 9 8 8 8 7 6 6 5 5 3 2 2 1 1 0
Research and Development (R&D) Expenses
M 25 25 28 29 27 25 21 21 18 18 15 15 9 10 5 5 4
Other Operating Expenses
M 0 9 -2 -1 -1 -3 - - - - - - - - - - -
Costs and Expenses
M 32 31 35 36 33 30 - - - - - - - - - - -
Operating Income
M -35 -35 -37 -37 -34 -32 -28 -27 -24 -23 -20 -18 -12 -12 -6 -5 -4
Interest Expense
M - 1 - - -1 2 1 1 0 0 0 0 0 0 0 0 0
Non-operating Income/Expense
M 3 2 2 0 2 2 1 1 0 0 0 0 -1 -8 0 0 0
EBT
M -32 -33 -35 -35 -32 -31 -27 -26 -24 -23 -20 -18 -12 -20 -7 -5 -4
Income Tax Provision
M 0 0 0 0 -2 -2 -1 -1 0 -1 -1 0 0 0 0 0 0
Income after Tax
M -32 -33 -35 -35 -30 -29 -26 -26 -24 -23 -19 -19 -12 -20 -7 -5 -4
Non-Controlling Interest
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Net Income
M - - - -35 -32 -31 -27 -26 -24 -23 -20 -18 -12 - -7 -5 -4
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 60,156,187.00 56,927,647.00 49,814,903.00 49,431,922.00 49,347,473.00 48,893,160.00 46,732,353.00 46,668,369.00 46,595,782.00 45,987,866.00 45,987,866.00 5,070,554.00 42,540,215.00 21,737,807.00 21,737,807.00 21,737,807.00 21,737,807.00
EBITDA
M -33 -33 -37 -36 -34 -32 -27 -26 -24 -23 -20 -17 -11 -12 -6 -5 -4
Depreciation and Amortization
M 2 2 2 1 0 0 1 1 1 1 1 0 0 0 0 0 0
EBIT
M -35 -35 -39 -37 -34 -32 -28 -27 -24 -24 -20 -18 -12 -12 -6 -5 -4
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% -0.26 0.07 0.49 -0.54 6.93 5.55 3.82 2.88 1.55 3.23 3.09 -1.53 1.53 -0.20 -2.62 0.60 -0.07
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Gross Profit Margin
% -78.29 78.91 - - - - - - - - - - - - - - -
Operating Income Margin
% -3,284.49 -398.34 - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - -
EBITDA Ratio
% -3,106.20 -377.25 - - - - - - - - - - - - - - -
EBIT Ratio
% -3,284.49 -398.34 - - - - - - - - - - - - - - -
EBT Ratio
% -2,996.71 -380.19 - - - - - - - - - - - - - - -

StockViz Staff

September 16, 2024

Any question? Send us an email